IDiyas

For the Inventor, By the Inventor

Frankfurt am Main, Germany

Stefan Guessregen

USPTO Granted Patents = 15 

 

Average Co-Inventor Count = 6.2

ph-index = 2

Forward Citations = 10(Granted Patents)


Location History:

  • Wiesbadan, DE (2008)
  • Wiesbaden, DE (2010 - 2011)
  • Frankfurt-am-Main, DE (2014 - 2022)

Company Filing History:

goldMedal10 out of 1,451 
 
Sanofi
 patents
silverMedal3 out of 1,827 
 
Sanofi-a Ventis Deutschland Gmbh
 patents
bronzeMedal1 out of 146 
 
Hanmi Pharm. Co., Ltd.
 patents
4. 1 out of 377 
 
Aventis Pharma S.a.
 patents
5. 1 out of 389 
 
Sanofi-aventis
 patents
where one patent can have more than one assignee

Years Active: 2008-2022

where 'Filed Patents' based on already Granted Patents

15 patents (USPTO):
1. 11396534 - Insulin analogs with reduced affinity to insulin receptor and use thereof (2022-07-26),
2. 11098102 - Insulin conjugates (2021-08-24),
3. 8901114 - Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof (2014-12-02),
4. 8895547 - Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof (2014-11-25),
5. 8871758 - Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof (2014-10-28),
6. 8846666 - Oxathiazine derivatives which are substituted with benzyl or heteromethylene groups, method for producing them, their use as medicine and drug containing said derivatives and the use thereof (2014-09-30),
7. 8828995 - Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof (2014-09-09),
8. 8828994 - Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof (2014-09-09),
9. 8809325 - Benzyl-oxathiazine derivatives substituted with adamantane and noradamantane, medicaments containing said compounds and use thereof (2014-08-19),
10. 8809324 - Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof (2014-08-19),
11. 8710050 - Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof (2014-04-29),
12. 7863280 - Substituted 2-pyridone derivatives, method for their preparation and their use as medicament (2011-01-04),
13. 7795278 - Substituted tetrahydro-2H-isoquinolin-1-one derivatives, and methods for the production and use thereof (2010-09-14),
14. 7759379 - Cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors (2010-07-20),
15. 7468369 - Sulfonyl pyrrolidines, method for producing the same and their use as drugs (2008-12-23),

Title: Innovations in Diabetes Treatment by Inventor Stefan Guessregen

Introduction

Stefan Guessregen, a prolific inventor based in Frankfurt am Main, Germany, has made significant contributions to the field of diabetes treatment with his innovative research and development. Holding an impressive portfolio of 14 patents, his work focuses primarily on insulin analogs and their applications.

Latest Patents

Among his latest inventions is an insulin analog with reduced affinity to the insulin receptor, which presents a novel approach to insulin therapy. This invention not only relates to the analog itself but also describes a method for its preparation. Another significant patent is for insulin conjugates, where his innovative conjugate features a sulfonamide formula and an active pharmaceutical ingredient, such as an insulin analog. The insulin analog described in this patent showcases mutations aimed at enhancing the therapeutic profile of insulin.

Career Highlights

Throughout his career, Guessregen has worked with notable companies, including Sanofi and Sanofi-Aventis Deutschland GmbH. His experience in these leading pharmaceutical organizations has undoubtedly influenced his innovative approach and deep understanding of diabetes treatment solutions.

Collaborations

Stefan has collaborated with esteemed colleagues including Thomas Boehme and Kurt Ritter. Together, they have advanced the field through their combined expertise and innovative insights, making strides that impact diabetic patient care.

Conclusion

Stefan Guessregen stands out as an influential figure in the realm of pharmaceutical innovations, particularly in diabetes management. His 14 patents reflect his dedication and contribution to improving therapeutic solutions for insulin-dependent individuals, forging a path for future advancements in treatment and care.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…